Table 1.
Parameters | Chemotherapeutic agent | P value | |
---|---|---|---|
|
|||
Miriplatin | Epirubicin | ||
Sex (male/female) | 30/17 | 43/21 | 0.839 |
Mean age (years) | 70.7 (35–88) | 70.1 (48–81) | 0.928 |
Hepatitis (B/C/NBNC) | 7/30/10 | 10/48/6 | 0.233 |
Child–Pugh class (A/B) | 33/14 | 46/18 | 1.000 |
Clinical stage (I/II/III/IV) | 11/32/18/5 | 16/45/16/2 | 0.110 |
Previous treatment (primary/recurrence) | 25/22 | 40/24 | 0.337 |
Mean tumor size (mm) | 17.6 (6–37) | 17.6 (7–46) | 0.999 |
Median AFP level (ng/mL) | 19 (4–2098) | 12 (3–6539) | 0.743 |
Median DCP level (mAU/mL) | 92 (6–1810) | 93 (5–4760) | 0.315 |
Chemoembolized area (segmental/subsegmental/distal) | 20/28/8 | 20/36/16 | 0.208 |
Number of treated tumors (1/2/3) | 30/15/2 | 51/11/2 | 0.071 |
Mean iodized oil dose (mL) | 2.9 (0.6–8.0) | 2.5 (0.6–6.0) | 0.060 |
Initial iodized oil uptake (good/fair) | 58/8 | 66/13 | 0.488 |
Notes: Data in brackets denote data range; no statistically significant difference was observed between the two groups for any of the parameters.
Abbreviations: AFP, α-fetoprotein; DCP, des-carboxy-prothrombin.